Strengths of our study are that patients with severe comorbidities such as cancer, severe autoimmune disorders, hepatic failure, end-stage renal disease, psychotic and bipolar disorders were excluded as these disorders, or medication for these disorders, may have impact on the immune system including MMPs and galectin-3 [7, 33]. This evidence concerns the gene LGALS3 and stage 5 chronic kidney disease.